OSE IMMUNOTHERAPEUTICS

Geld 5,90
Brief 6,00
ESG ACHIEVEMENTS AND GOALS
ur goal is to develop innovative treatment options for patients suffering from severely debilitating diseases with a high medical need, and to provide physicians with new, effective and life-saving treatments for their patients.
Outside our core business of curing patient, the company is committed to optimizing and structuring its existing Corporate Social and Environmental Responsibility (CSR) approach.
Concerning environment purpose, R&D activities do not include industrial production or distribution. Consequently, resource consumption is relatively limited. However, the company is careful to respect the prerogatives initiated by the government, and asks its employees to behave responsibly with regard to ecological constraints. OSE uses also very few raw materials, and its business does not generate any significant environmental emissions or greenhouse gases. Since 2018, environmental concerns have led the company to purchase bicycles, which are made available to employees for short-distance journeys during working hours.
The introduction of telecommuting reduces the environmental impact of daily home-office journeys. Similarly, the internal travel policy promotes the use of trains whenever possible, as opposed to planes or cars. Finally, OSE does not own a fleet of cars.
Concerning social purpose, OSE Immuno recruits mainly on open-ended contracts, enabling the company to build long-term employee relations (95% open-ended contracts by January 2023). Every year, the company also takes on a number of work-study students and interns and trainees at various levels. The proportion of women in the teams is high: 66% of team members are women, 60% of the executive committee members are women, and 85% of managers are women.
In addition, the age pyramid is balanced, with OSE recruiting both talented young graduates and highly experienced employees (for example, employees over 50 represented 19% of the permanent workforce at 12/31/2022).
A Social and Economic Committee (CSE) has been in place since December 2019, with 4 elected members. Its role is to ensure the collective expression of employees, enabling their interests to be taken into account in decisions relating to the management and economic and financial development of the Company, work organization and professional training.
The company has also set up various initiatives to promote a working environment that preserves the balance between professional and private life, to improve their quality of life at work (sick leave for parents, teambuilding, seminar, teleworking Charter, etc.)
Concerning gouvernance purpose, OSE's executive committee comprises 4 members, including 2 women. The average age of the members is 44 and the 4 members of the executive committee combine expertise in all areas of the company
OSE is also managed by a Board of Directors whose members come from different backgrounds and have a variety of skills, reflecting its objectives. It is composed of 9 members, 7 of whom are independent, and the average age is 63. With 4 women and 5 men, the Company complies with law n° 2011-103 of January 27, 2011, which stipulates that the Board must include at least 40% of each gender.
OSE CSR manager takes part of OSE's executive committee and Board of Directors.
The Company has also developed an internal supplier management procedure, which applies to all OSE employees or subcontractors involved in supplier management (selection, qualification and monitoring), for all services where Good Practices must be respected, whether for services, sales of goods or equipment. It includes notably ethic, fair market and CSR value.
With regard to cybersecurity and training, all of the company's employees were made aware of the cybersecurity risk by the DGSI in 2021 and regular information is sent by the IT department on the subject.
And OSE Immunotherapeutics is committed to the protection of personal data and the respect of privacy. All employees are involved in respecting the rules relating to the protection of personal data, which are formalized in a procedure. A Data Protection Officer has been appointed to implement the necessary measures and ensure compliance and monitoring of the rules in this area.
DOCUMENTS
FINANCIAL INDICATORS
Indicator | Unit | 2023 | 2022 | 2021 |
---|---|---|---|---|
Annual revenue | Thousand (EUR) | 2 227 | 18 302 | 26 306 |
Enterprise value at fiscal year-end | Thousand (EUR) | 138 468 | 168 463 | 225 103 |